I’m putting together a list of stem cell and regenerative medicine biotech companies for a blog post, including both public and private. I’ve got a good list already, but want it to be fairly comprehensive.
I’m also curious what readers think are the most promising ones and why. So weigh in with comments please or email me. Ideally, you would indicate if you have an investment in these stocks for the publicly-traded ones. Don’t restrict yourself only to stocks traded on US markets necessarily and private companies like ViaCyte are exciting as well so should be included.
It’s also interest to see how these lists change over time reflecting shifts and trends in the industry. For instance, Ocala (fka as ACT) is gone. StemCells, Inc. is gone. CDI is gone as an independent entity at least.
Look for a future post with a stem cell/regenerative medicine biotech list. If you invest in this sector be aware it is extremely risky and over the years most of these kinds of stocks have tended to go down more than up.
What’s the deal with Trump’s HHS Secretary pick Rep. Tom Price (now testifying before the Senate) and the amniotic tissue/stem cell company MiMedx that’s caused some buzz in the last 48 hours?
I’ve been following MiMedx for a few years since it received an untitled letter from the FDA and I noted its claim of one its product acting like a “stem cell magnet.” More recently I did a 2nd post mentioning the company a few months back focusing on its contributions to former Sen. Mark Kirk, whose legislative baby the REGROW Act would have codified risky reductions in stem cell oversight by the FDA.
Now Kaiser Health News (KHN) just reported that Price received more than $40,000 in total contributions from the MiMedx PAC, the MiMedx CEO and others linked to the company for his congressional election campaign:
“With combined PAC and individual donations, the company (MiMedx) was ranked as Price’s top contributor for 2015-2016 by the nonpartisan Center for Responsive Politics.”
According to KHN, the MiMedx CEO Parker H. “Pete” Petit allegedly pressured employees to contribute to the company’s PAC, potentially raising questions about election contribution rules. RollCall first reported on the Price-MiMedx connection in mid-December. While this KHN story seems more about the MiMedx PAC than about Tom Price, since Price is reportedly the top receiver of MiMedx PAC funds, the connection is worth some thought.
Is there a stem cell connection here? Could some companies in the stem cell/regenerative medicine arena hope that Price will exert pressure on the FDA to soften oversight?
And what exactly are Price’s views on stem cells?
One of my Top 20 Predictions for Stem Cells for 2017 was that we’d see more instances of fake stem cell news.
One type of stem cell fake news consists of promotional press releases that seek to recruit paying customers for unproven stem cell “treatments” based on made up or exaggerated claims about safety and efficacy or about the stem cell clinic’s credentials.
Another kind of fake stem cell news is more ideologically based and is mainly practiced by anti-embryonic stem cell (ESC) websites that have news-like items stating that ESCs have been proven not to work at all or to always cause tumors, while adult stem cells will save the world.
For whatever reason Google sometimes even includes both these types of bogus items in its news feed and I’m sure the same thing happens on Facebook. I’m going to be posting about instances of fake stem cell news over the course of this year.
Seen what you think might be stem cell fake news? Let me know.
CIRM is doing a fun, positive challenge to the stem cell community to post stem cell resolutions for the new year. You can read more about it here.
Be sure if you post yours on Twitter to include the #StemCellResolution hashtag. Have fun!
Below is my resolution in video form.